Development and validation of a stability-indicating LC method for the assay of lodenafil carbonate in tablets

Journal of Chromatographic Science

Volumn 49, Issue 7, 2011, Pages 502-507

  Codevilla, Cristiane Franco ^a,b   Lemos, Alice MacHado ^a,b   Delgado, Leila Schreiner ^a,b   Rolim, Clarice Madalena Bueno ^a,b   Adams, Andréa Inês Horn ^a,b   Bergold, Ana Maria ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIS (2 (4 (4 ETHOXY 3 (1 METHYL 7 OXO 3 PROPYL 6,7 DIHYDRO 1H PYRAZOLO(4,3 D)PYRIMIDIN 5 YL) BENZENESULFONYL)PIPERAZIN 1 YL) ETHYL)CARBONATE; BIS-(2-(4-(4-ETHOXY-3-(1-METHYL-7-OXO-3-PROPYL-6,7-DIHYDRO-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-BENZENESULFONYL)PIPERAZIN-1-YL)-ETHYL)CARBONATE; CARBONIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CHEMISTRY; DRUG STABILITY; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHODOLOGY; TABLET; VALIDATION STUDY;

CARBONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; PIPERAZINES; PYRIMIDINES; TABLETS;

EID: 80053618585     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chrsci/49.7.502     Document Type: Article

References (13)

1. C. Foresta, N. Caretta, G. Corona, A. Fabbri, S. Francavilla, E. Jannini, M. Maggi, C. Bettocchi, and A. Lenzi. Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart. Int. J. Androl. 32(3): 198-211 (2009).
2. E.D. Moreira Jr., C.F.L. Lôbo, A. Diament, A. Nicolosi, D.B. Glasser. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 61(2): 431-436 (2003). (Pubitemid 36206547)
3. C.H.N. Abdo, W.M. Oliveira Jr., M.T. Scanavino, and F.G. Martins. Disfunção erétil - resultados do estudo da vida sexual do brasileiro. Rev. Assoc.Med. Bras. 52(6): 424-429 (2006).
4. G. Brock. Oral agents: first-line therapy for erectile dysfunction. Eur. Urol. Suppl. 1(8): 12-18 (2002). (Pubitemid 36056425)
5. I. Eardley. Erectile dysfunction: where are we going? JMHG. 3(4): 323-325 (2006). (Pubitemid 44716784)
6. C.C. Carson. Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol. Clin. N. Am. 34: 507-515 (2007).
7. S. Glina, I. Toscano, C. Gomatzky, P.M. Góes, A. Nardozza Jr., J.F.A. Claro, and E. Pagani. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J. Sex.Med. 6: 553-557 (2009).
8. L.A. Levine. Erectile dysfunction: a review of a common problem in rapid evolution. Prim. Care Update OB/GYNS. 7(3): 124-129 (2000). (Pubitemid 30326724)
9. W.O. Brant, A.J. Bella, and T.F. Lue. Treatment options for erectile dysfunction. Endocrinol.Metab. Clin. N. Am. 36: 465-479 (2007). (Pubitemid 46817881)
10. S. Singh, B. Prasad, A.A. Savaliya, R.P. Shah, and V.M. Gohil, A. Kaur. Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs. Trends Anal. Chem. 28(1): 13-28 (2009).
11. H. Toque, C.E. Teixeira, R. Lorenzetti, C.E. Okuyama, E. Antunes, and G. De Nucci. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur. J. Pharmacol. 591: 189-195 (2008).
12. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: text and methodology Q2(R1) (2005).
13. G.A. Shabir. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J. Chromatog. A. 987: 57-66 (2003). (Pubitemid 36140080)